Cargando…
Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
BACKGROUND: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality. We aimed to evaluate the effect of immune dysfunction on imm...
Autores principales: | Lin, Kuan-Yin, Hsieh, Ming-Ju, Chang, Sui-Yuan, Ieong, Si-Man, Cheng, Chien-Yu, Sheng, Wang-Huei, Chang, Shan-Chwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Formosan Medical Association. Published by Elsevier Taiwan LLC.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428601/ https://www.ncbi.nlm.nih.gov/pubmed/36089471 http://dx.doi.org/10.1016/j.jfma.2022.08.017 |
Ejemplares similares
-
Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval
por: Sheng, Wang-Huei, et al.
Publicado: (2023) -
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022) -
Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster
por: Singh, Arminder, et al.
Publicado: (2022) -
Editorial commentary on Indian Journal of Gastroenterology—July–August 2021
por: Limdi, Jimmy K.
Publicado: (2021) -
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)